Xiao-Yong Rao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiao-Yong Rao has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Xiao-Jian Luo
National Pharmaceutical Engineering Center for Solid Preparation in Chinese Herbal Medicine, Nanchang 330006, China
2 shared publications - Dongxun Li
National Engineering Research Center of Chinese Medicine Solid Preparation Manufacturing Technology, Jiangxi University of Chinese Medicine, Nanchang 330006, China
1 shared publication - Guosong Zhang
National Engineering Research Center of Chinese Medicine Solid Preparation Manufacturing Technology, Jiangxi University of Chinese Medicine, Nanchang 330006, China
1 shared publication Haowei Lu
Department of Pharmacy, The Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang 330006, China
1 shared publicationMeng Gao
National Pharmaceutical Engineering Center for Solid Preparation in Chinese Herbal Medicine, Jiangxi University of Chinese Medicine, Nanchang 330006, China
1 shared publication- Mingzhen He
Jiangxi University of Chinese Medicine, No. 818 Yunwan Road, Nanchang, 330002, PR Chin; National Pharmaceutical Engineering Center for Solid Preparation of Chinese Herbal Medicine, No. 56 Yangming Road, Nanchang, 330006, PR China
1 shared publication
Latest Publications
- 19 September 2024
- Published by Elsevier in Nitric Oxide
- Vol. 152, 48-57
Nitric oxide in the cardio-cerebrovascular system: Source, regulation and application
- 19 September 2024
- Published by Elsevier in Nitric Oxide
- Vol. 152, 48-57
Nitric oxide in the cardio-cerebrovascular system: Source, regulation and application
- Open Access
Formulations, Hemolytic and Pharmacokinetic Studies on Saikosaponin a and Saikosaponin d Compound Liposomes
The aim of this study was to develop and optimise a saikosaponin a and saikosaponin d compound liposome (SSa-SSd-Lip) formulation with reduced hemolysis and enhanced bioavailability. A screening experiment was done with Plackett–Burman design, and response surface methodology of five factors (EPC/SSa-SSd ratio, EPC/Chol ratio, water temperature, pH of PBS, and ultrasound time) was employed to optimise the mean diameter, entrapment efficiency of SSa and SSd, and the reduction of hemolysis for SSa-SSd-Lip. Under the optimal process conditions (EPC/SSa-SSd ratio, EPC/Chol ratio, water temperature and pH of PBS were 26.71, 4, 50 °C and 7.4, respectively), the mean diameter, the entrapment efficiency of SSa, the entrapment efficiency of SSd and the hemolysis were 203 nm, 79.87%, 86.19%, 25.16% (SSa/SSd 12.5 mg/mL), respectively. The pharmacokinetic studies showed that the SSa-SSd-Lip had increased circulation time, decreased Cl, and increased AUC, MRT and T1/2β (p < 0.05) for both SSa and SSd after intravenous administration in comparison with solution.
Open AccessFormulations, Hemolytic and Pharmacokinetic Studies on Saikosaponin a and Saikosaponin d Compound Liposomes
The aim of this study was to develop and optimise a saikosaponin a and saikosaponin d compound liposome (SSa-SSd-Lip) formulation with reduced hemolysis and enhanced bioavailability. A screening experiment was done with Plackett–Burman design, and response surface methodology of five factors (EPC/SSa-SSd ratio, EPC/Chol ratio, water temperature, pH of PBS, and ultrasound time) was employed to optimise the mean diameter, entrapment efficiency of SSa and SSd, and the reduction of hemolysis for SSa-SSd-Lip. Under the optimal process conditions (EPC/SSa-SSd ratio, EPC/Chol ratio, water temperature and pH of PBS were 26.71, 4, 50 °C and 7.4, respectively), the mean diameter, the entrapment efficiency of SSa, the entrapment efficiency of SSd and the hemolysis were 203 nm, 79.87%, 86.19%, 25.16% (SSa/SSd 12.5 mg/mL), respectively. The pharmacokinetic studies showed that the SSa-SSd-Lip had increased circulation time, decreased Cl, and increased AUC, MRT and T1/2β (p < 0.05) for both SSa and SSd after intravenous administration in comparison with solution.